Abstract
Growing evidence suggests that the gut microbiome is an important
contributor to metabolic diseases. Alterations in microbial
communities are associated with changes in lipid metabolism,
glucose homeostasis, intestinal barrier functions,
and chronic inflammation, all of which can lead to metabolic
disorders. Therefore, the gut microbiome may represent a
novel therapeutic target for obesity, type 2 diabetes, and nonalcoholic
fatty liver disease. This review discusses how gut microbes
and their products affect metabolic diseases and outlines
potential treatment approaches via manipulation of the
gut microbiome. Increasing our understanding of the interactions
between the gut microbiome and host metabolism
may help restore the healthy symbiotic relationship between
them.
Citations
Citations to this article as recorded by

- Fecal Microbiota Transplantation: Indications, Methods, and Challenges
Jee Young Lee, Yehwon Kim, Jiyoun Kim, Jiyeun Kate Kim
Journal of Microbiology.2024; 62(12): 1057. CrossRef - Galectin-4 increases the ability of M2 macrophages to enhance antiviral CD4+ T-cell responses
In-Gu Lee, Yong-Hyun Joo, Hoyeon Jeon, Raehyuk Jeong, Eui Ho Kim, Hyunwoo Chung, Seong-il Eyun, Jeongkyu Kim, Young-Jin Seo, So-Hee Hong
Journal of Leukocyte Biology.2023; 113(1): 71. CrossRef - Microencapsulation of Bacteriophages for the Delivery to and Modulation of the Human Gut Microbiota through Milk and Cereal Products
Christina Schubert, Sabina Fischer, Kathrin Dorsch, Lutz Teßmer, Jörg Hinrichs, Zeynep Atamer
Applied Sciences.2022; 12(13): 6299. CrossRef - Beta-Glucan Alters Gut Microbiota and Plasma Metabolites in Pre-Weaning Dairy Calves
Zhengzhong Luo, Li Ma, Tao Zhou, Yixin Huang, Liben Zhang, Zhenlong Du, Kang Yong, Xueping Yao, Liuhong Shen, Shumin Yu, Xiaodong Shi, Suizhong Cao
Metabolites.2022; 12(8): 687. CrossRef